The Column Group

General contacts

Investor type

Founded

2006

AUM

$4 000 M

Location

San Francisco, California, United States

Investment Ticket

$10-50 m

Investment Stage

Seed Pre-seed Series A Series B Late Stage (Series C+)

Region of investment

North America

Investor profile last updated: 16 August, 2026

Profile

The Column Group (TCG) is a venture capital firm based in San Francisco, California, founded in 2007 by Peter Svennilson. The firm focuses on early-stage investments in the life sciences sector, particularly in biotechnology and drug discovery. TCG is known for its unique approach to venture capital, emphasizing long-term investments and company formation rather than quick exits. The team comprises 23 professionals, including partners with deep scientific and financial expertise.

TCG invests primarily in the United States, targeting sectors such as healthcare, life sciences, oncology, and technology-based industries. The firm operates an ecosystem of funds, including TCG Platform funds, TCG Opportunity funds, and TCG Labs-Soleil, which support technology platforms and later-stage programs. TCG has generated $4 billion in returns for its partners and manages several funds, including The Column Group IV and The Column Group Opportunity III.

Notable portfolio companies include Carmot Therapeutics - drug discovery, Peloton Therapeutics - oncology, Aragon Pharmaceuticals - prostate cancer treatments, Neurona Therapeutics - cell therapy, and Constellation Pharmaceuticals - epigenetics. TCG's investments have led to 18 successful exits, showcasing its impact on the biotech industry.

Industry

Biotechnology Healthcare Services Marketing and Advertising Medical Devices Pharmaceuticals MedTech Life Sciences HealthTech Media and Entertainment

The Column Group Funds

Name	Type	Industry	Stage	Region	Size	AUM	Launch date
The Column Group IV	Venture Capital (VC)	Biotechnology Healthcare Services Media and Entertainment HealthTech	Pre-seed Seed	North America	$5-10 m	$725 M	December 2019
The Column Group Opportunity III	Fund of funds	Biotechnology Healthcare Services Marketing and Advertising Media and Entertainment HealthTech	Seed Series A Series B	North America	$5-10 m	$615 M	January 2022
The Column Group X	Venture Capital (VC)	Biotechnology Healthcare Services Marketing and Advertising HealthTech	Pre-seed Seed	North America	$5-10 m	$400 M	January 2024
The Column Group V	Venture Capital (VC)	Biotechnology Healthcare Services Marketing and Advertising HealthTech	Pre-seed Seed	North America	$5-10 m	$615 M	July 2022

Contacts

Name

Title

Social Networks

Peter Svennilson Founder / Managing Partner

Founder / Managing Partner

p•••@•••

Tim Kutzkey, PhD Managing Partner

Managing Partner

t•••@•••

Upgrade to see contacts

H9A2OwqxUSmQ1RBh H9A2OwqxUSmQ1RBh

H9A2OwqxUSmQ1RBh

[email protected]

H9A2OwqxUSmQ1RBh H9A2OwqxUSmQ1RBh

H9A2OwqxUSmQ1RBh

[email protected]

H9A2OwqxUSmQ1RBh H9A2OwqxUSmQ1RBh

H9A2OwqxUSmQ1RBh

[email protected]

Investment-team contacts for The Column Group — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.

Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about The Column Group

Is The Column Group a venture capital or private equity firm?

The Column Group is a venture capital firm. It backs companies at Seed, Pre-seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.

Where is The Column Group located?

The Column Group is located in San Francisco, California, United States.

When was The Column Group founded?

The Column Group was founded in 2006.

What sectors and industries does The Column Group invest in?

The Column Group invests in companies and startups in Biotechnology, Healthcare Services, Marketing and Advertising, Medical Devices, Pharmaceuticals, MedTech, Life Sciences, HealthTech, Media and Entertainment.

What is The Column Group geographical focus of investments?

The Column Group invests in companies and startups in North America.

At what stages of companies and startups does The Column Group typically invest in?

The Column Group invests in companies and startups at Seed, Pre-seed, Series A, Series B, Late Stage (Series C+).

What is the usual amount of The Column Group investment?

The Column Group usually invests $10-50 m on average.

What is the amount of assets of under management (AUM) for The Column Group?

The Column Group has around $4 000m assets under management.

When was The Column Group last fund created?

The Column Group last fund was created/launched in 2024-01-12

What are the contacts of The Column Group?

The Column Group can be reached through its website thecolumngroup.com and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for The Column Group — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

Can I access The Column Group data via API or MCP?

Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query The Column Group directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.

When was the The Column Group profile last updated?

Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 16 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.